<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900911-0046</DOCNO><DOCID>900911-0046.</DOCID><HL>   Technology Brief -- Baxter International Inc.:   Stake in Genetics Institute   Is Cut to 3.5% From 7%</HL><DATE>09/11/90</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   GENI BAX</CO><IN>TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)MEDICAL AND BIOTECHNOLOGY (MTC)</IN><LP>   Baxter International Inc. said it cut its stake inGenetics Institute Inc. to 3.5% from 7% of the common sharesoutstanding.   In a filing with the Securities and Exchange Commission,Baxter said it sold 521,374 shares Friday at $31.25 a share.As a result, Baxter, a medical products and services concernbased in Deerfield, Ill., now holds 500,000 shares inGenetics Institute, a pharmaceuticals company in Cambridge,Mass.</LP><TEXT>   As previously reported, Baxter has said that it intends tosell all or part of its investment in Genetics Institute andthat the proceeds from the sale will be used to reduce debt.   In making the announcement last month, Baxter said thecompany has an &quot;excellent working relationship&quot; with GeneticsInstitute. The two companies are involved in a joint effortto develop and market a genetically engineered drug on whichGenetics Institute holds a patent. The drug is forhemophilia, a hereditary condition in which one of the normalblood-clotting factors is absent.</TEXT></DOC>